FranceTuberculosis profile
Population  2015 64 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.52 (0.49–0.55) 0.8 (0.76–0.85)
Mortality (HIV+TB only) 0.056 (<0.01–0.27) 0.09 (0–0.41)
Incidence  (includes HIV+TB) 5.3 (4.7–6) 8.2 (7.2–9.3)
Incidence (HIV+TB only) 0.41 (0.32–0.5) 0.63 (0.49–0.78)
Incidence (MDR/RR-TB)** 0.088 (0.063–0.11) 0.14 (0.1–0.17)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.2 (0.12–0.28) 1.8 (1.3–2.3) 2 (1.5–2.6)
Males 0.2 (0.14–0.26) 3 (2.4–3.7) 3.2 (2.5–4)
Total 0.4 (0.3–0.5) 4.9 (4.5–5.3) 5.3 (4.7–6)
TB case notifications, 2015  
Total cases notified 4 788
Total new and relapse 4 494
          - % tested with rapid diagnostics at time of diagnosis 0%
          - % with known HIV status  
          - % pulmonary 73%
          - % bacteriologically confirmed among pulmonary 76%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 85% (75–96)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.11 (0.08–0.14)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  63
(47–79)
Estimated % of TB cases with MDR/RR-TB 1% (0.65–1.5) 10% (7.1–15)  
% notified tested for rifampicin resistance <1% 10% 96
MDR/RR-TB cases tested for resistance to second-line drugs   95
Laboratory-confirmed cases MDR/RR-TB: 96, XDR-TB: 9
Patients started on treatment **** MDR/RR-TB: 96, XDR-TB: 9
Treatment success rate and cohort size Success Cohort
New cases registered in 2014    
Previously treated cases registered in 2014    
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data